Premium
Plasma levels of tumour necrosis factor alpha and interleukin‐6 predict progression‐free survival following thalidomide therapy in patients with previously untreated multiple myeloma
Author(s) -
Thompson Michael A.,
Witzig Thomas E.,
Kumar Shaji,
Timm Michael M.,
Haug Jessica,
Fonseca Rafael,
Greipp Philip R.,
Lust John A.,
Rajkumar S. Vincent
Publication year - 2003
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1046/j.1365-2141.2003.04605.x
Subject(s) - thalidomide , multiple myeloma , medicine , oncology , tumor necrosis factor alpha , interleukin 6 , progression free survival , interleukin , alpha (finance) , immunology , cancer research , chemotherapy , cytokine , surgery , construct validity , patient satisfaction
Summary. We studied marrow angiogenesis and plasma levels of angiogenic cytokines in 38 patients receiving thalidomide therapy for previously untreated myeloma. The effect of therapy and the relationship of cytokine levels to myeloma cell proliferation, bone marrow microvessel density and progression‐free survival (PFS) were studied. High pretreatment tumour necrosis factor‐α (TNFα) levels (> 11 pg/ml) and increased interleukin (IL)‐6 of > 2 pg/ml predicted for poorer PFS (TNFα, 48% versus 74% at 2 years, P = 0·01; IL‐6, 24% versus 70% at 2 years, P = 0·01). None of the other parameters predicted response or PFS, and no significant changes in cytokine levels occurred with therapy.